PDT 99 - $3.5M - Seed - Feel Therapeutics.pdf

PDT 99 - $3.5M - Seed - Feel Therapeutics.pdf

1. DECODINGMENTAL HEALTH
Digital Precision Medicine for Mental Health

2. 1 out of 4 of uswill experience a mental disorder1
Mental illness will be the leading cause of disability by 20301 costing $6 Trillion
Sources: 1WHO Global burden of disease, 2ncbi.nlm.nih.gov/pmc/articles/PMC4392551
>45% of patients with chronic conditions struggle with behavioralhealth2

3. THERMOMETERSTETHOSCOPEBLOOD PRESSURE
MONITOR
GLUCOSE
METER
MENTAL
HEALTH
?
EVERY OTHER MEDICAL PRACTICE USES
OBJECTIVE MEASUREMENT TOOLSNo objective
monitoring
for mental health
PROBLEM

4. TECHNOLOGY
Feel’s proprietary
Digital Precision
Medicine Platform
brings continuous
and passive
monitoring to
mental health.
MOOD
MENTAL STRESSSLEEP
PHYSICAL
SYMPTOMS
SOCIAL ACTIVITY
PSYCHOMOTOR
ACTIVITY
COGNITIVE FUNCTIONING
PSYCHOPHYSIOLOGICAL
MONITORING
Digital BiomarkersProprietary AlgorithmsContinuous Monitoring
Wearable
Devices
Sensors of the
Mobile Phone
Voice, Video &
Text
VITALS
PHYSICAL ACTIVITYBODY ENERGY

5. 1. REMOTE MONITORING
DEVICE & APP
2. PROPRIETARY
ALGORITHMS
3. REAL-TIME SUPPORT
& ADHERENCE
TOOLS
5. DIGITAL CBT
PROGRAM &
PSYCHO-
EDUCATION
4. CLINICIAN’S
DASHBOARD &
COACHING
Sleep
Physical &
psychomotor activity
Stress
Emotions
Social activity
SOLUTION | LINKING REMOTE MONITORING WITH PRECISE INTERVENTION 24/7/365
6. MEDICATION

6. IMPACT TO PATIENTS ACROSS MENTAL HEALTH CONDITIONS
MDD
Countries:5Subjects:817
Total countries
9
Total Patients
2,727
23
Research &
clinical
studies
Active 2018-
2024
PTSD
Countries:1Subjects:95
Healthy w/ risk factors
Countries:5Subjects:1154
ADHD
Countries:1Subjects:100
Eating Disorders
Countries:1Subjects:80
MDDGADPTSDADHD
Eating Disorders
Number of studies
Healthy w/ risk factors
GAD
Countries:5Subjects:427
6
THERAPEUTIC
AREAS IN CNS
6
TAs PIPELINE
(e.g. Oncology,
Hematology et al.)
*Starting in 2024
MS*
Countries: 1 Subjects: 50
5
6
3
7
111
0
2
4
6
8
MS

7. PUBLICATIONS
Precision DTx
delivers superior
improvement in
outcomes in
depression and/or
anxiety
Read Publication
87% precision in
detecting
changes in the
mood state of
patients in
psychiatry
Read Publication
Psychophysiologi
cal index for
Stress
Emotion
Detection 2
Outcomes of Feel
DTx for
Depression and
Anxiety
Precision and
accuracy of
emotional state
detection and
recognition
Psychophysiologi
cal index for
Stress Resilience
Psychophysiologi
cal index for
Stress strongly
correlates with
changes in
Cortisol levels
Read Publication
Psychophysiologi
cal index for
Stress
Electrodermal
Activity (EDA)
can be a stress
resilience metric
in stressful
conditions
Read Publication
Psychophysiologi
cal index for
Stress strongly
correlates with
changes in the
Endocannabinoid
System
Read Publication
Precision DTx
shows
improvement in
mental health
outcomes for
ADHD
populations
Read Publication
Outcomes of Feel
DTx for ADHD
Digital Biomarker
for Detection of
ADHD
Detection of
ADHD utilizing
physiological
signals from
wearables
Publication
Pending

8. PATENTS
Patent for
detecting
changes in the
mood state of an
individual based
on physiological &
digital data
Patent No:
US1141068282
Method for
detecting and
recognizing an
emotional state
of a user
(Continuation)
Patent Granted
Depression
Relapse Digital
Biomarker
Emotion
Detection 2
Emotion
Detection
Emotion
Detection 2
ADHD Digital
Biomarker
Method for
characterizing,
detecting, and
monitoring ADHD
Patent pending
Insomnia Digital
Biomarker
System and
method for
characterizing,
detecting, and
monitoring
insomnia
Patent pending
System and
method for
characterizing,
detecting, and
monitoring
relapse in
depression
Patent pending

9. STATS
TEAM
INVESTORS
CORE TEAM
800+
TEAM MEMBER
PUBLICATIONS16000+
TEAM MEMBER
CITATIONS
9
POST-DOCS
IN THE CORE TEAM4
PROFESSORS OF
PSYCHIATRY
31
TEAM MEMBERS
IN THE USA & EUROPE$180k
CORE GROSS
MONTHLY BURN RATE
A COMPANY OF:GEORGE
ELEFTHERIOU
CO-FOUNDER & CEO
FORMER MCKINSEY,
COLUMBIA
SHARON KAPLOW
VP OF CLINICAL
OPERATIONS,
FORMER CLINICAL
LEAD AbleTo
HARIS TSIRBAS, PhD
CO-FOUNDER & CTO
PHD IN BIOMEDICAL
ENGINEERING
LEADERSHIP TEAM
INDUSTRY EXPERTS
MICHEL
VOUNATSOS
FORMER CEO OF
BIOGEN
DR. NIKOS
DASKALAKIS
PROFESSOR OF
PSYCHIATRY AT
HARVARD
STAYCE BECK
FORMER DIRECTOR
PERSONALIZED
MEDICINE &
BIOMARKERS @ FDA
PSYCHIATRY EXPERTS
DR. PETER
YELLOWLEES
PROFESSOR OF
PSYCHIATRY AT
UC DAVIS
DR. JOAQUIN
ANGUERA
PROFESSOR OF
PSYCHIATRY AT
UCSF
TORSTEN
OLETZKY
FORMER CEO OF
ERGO

10. EXISTING ROUND
MILESTONES
FDA approval of our wearable as a 510k class II medical device
Launch as a Drug+ in the market & clearance of Feel DTx
program as an adjunct to medication
PRE-SERIES A
FUNDRAISING
$1M left in a
$3.5M round to
reach an
inflection pointEmpatica closed their series B financing from Sanofi after receiving
FDA clearance for a similar device
Recent FDA clearance of DTx for the Adjunctive Treatment of MDD
Terms: Convertible Note with $30M Cap and 20% Discount
Closed $2.5M led by expert Neurotech investors (Satori Neuro)

11. George Eleftheriou, Co-Founder & CEO
479 Jessie Street, San Fransisco, CA 94103
[phone] | [email protected] | www.feeltherapeutics.com